GlobeNewswire: Basilea Pharmaceutica Ltd. Contains the last 10 of 19 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:52:58ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/09/20/872995/10165199/en/Basilea-announces-distribution-agreement-with-Unimedic-for-CRESEMBA-R-isavuconazole-and-Zevtera-R-ceftobiprole-in-the-Nordic-countries.html?f=22&fvtc=4&fvtv=20088Basilea announces distribution agreement with Unimedic for CRESEMBA(R) (isavuconazole) and Zevtera(R) (ceftobiprole) in the Nordic countries2016-09-20T05:18:56Z<![CDATA[BASEL, Switzerland, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license and distribution agreement with Unimedic Pharma AB (Unimedic) for Basilea's antifungal CRESEMBA]]>https://www.globenewswire.com/news-release/2016/09/13/871319/10165069/en/Basilea-announces-supply-distribution-and-license-agreement-with-Grupo-Biotoscana-for-CRESEMBA-R-isavuconazole-and-Zevtera-R-ceftobiprole-in-Latin-America.html?f=22&fvtc=4&fvtv=20088Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA(R) (isavuconazole) and Zevtera(R) (ceftobiprole) in Latin America2016-09-13T05:24:01Z<![CDATA[BASEL, Switzerland, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a supply, distribution and license agreement with Grupo Biotoscana S.L., (GBT) for Basilea's antifungal CRESEMBA]]>https://www.globenewswire.com/news-release/2016/08/17/864679/10164594/en/Basilea-announces-distribution-agreement-with-Hikma-for-CRESEMBA-r-isavuconazole-in-the-MENA-region.html?f=22&fvtc=4&fvtv=20088Basilea announces distribution agreement with Hikma for CRESEMBA(r) (isavuconazole) in the MENA region2016-08-17T05:19:04Z<![CDATA[
BASEL, Switzerland, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the company has extended its distribution and supply agreement for the Middle East and North Africa (MENA) region with Hikma Pharmaceuticals LLC (Hikma) to include the antifungal CRESEMBA]]>https://www.globenewswire.com/news-release/2016/08/15/864010/10164552/en/Basilea-reports-2016-half-year-results-CRESEMBA-R-launched-in-key-European-markets.html?f=22&fvtc=4&fvtv=20088Basilea reports 2016 half-year results - CRESEMBA(R) launched in key European markets2016-08-15T05:33:12Z<![CDATA[
BASEL, Switzerland, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the first half of financial year 2016 with a solid half-year cash position of CHF 310.9 million and a net loss of CHF 27.9 million.]]>https://www.globenewswire.com/news-release/2016/06/27/851303/10163715/en/Basilea-s-antifungal-CRESEMBA-r-isavuconazole-launched-in-Italy.html?f=22&fvtc=4&fvtv=20088Basilea's antifungal CRESEMBA(r) (isavuconazole) launched in Italy2016-06-27T05:22:03Z<![CDATA[BASEL, Switzerland, June 27, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announces that it has launched its new azole antifungal CRESEMBA]]>https://www.globenewswire.com/news-release/2016/03/09/818067/10160853/en/Basilea-announces-that-The-Lancet-Infectious-Diseases-published-results-from-the-CRESEMBA-R-isavuconazole-open-label-study-for-the-treatment-of-mucormycosis.html?f=22&fvtc=4&fvtv=20088Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA(R) (isavuconazole) open-label study for the treatment of mucormycosis2016-03-09T06:19:58Z<![CDATA[BASEL, Switzerland, March 9, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that results from the open-label phase 3 VITAL study evaluating CRESEMBA]]>https://www.globenewswire.com/news-release/2016/03/04/816841/10160705/en/Basilea-launching-antifungal-CRESEMBA-R-isavuconazole-in-Germany.html?f=22&fvtc=4&fvtv=20088Basilea launching antifungal CRESEMBA(R) (isavuconazole) in Germany2016-03-04T06:18:07Z<![CDATA[BASEL, Switzerland, March 4, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) hosts a symposium to support the launch of the new azole antifungal CRESEMBA]]>https://www.globenewswire.com/news-release/2016/03/03/816417/10160655/en/Basilea-launching-antifungal-CRESEMBA-r-isavuconazole-in-the-United-Kingdom.html?f=22&fvtc=4&fvtv=20088Basilea launching antifungal CRESEMBA(r) (isavuconazole) in the United Kingdom2016-03-03T06:21:25Z<![CDATA[BASEL, Switzerland, March 3, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) hosts a symposium to support the launch of the new azole antifungal CRESEMBA]]>https://www.globenewswire.com/news-release/2016/02/29/814853/10160517/en/Basilea-reports-solid-2015-full-year-results-and-is-launching-CRESEMBA-r-its-second-hospital-anti-infective-in-Europe.html?f=22&fvtc=4&fvtv=20088Basilea reports solid 2015 full-year results and is launching CRESEMBA(r), its second hospital anti-infective, in Europe2016-02-29T06:22:07Z<![CDATA[
BASEL, Switzerland, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the financial year 2015 with a solid year-end cash position of 364.7 million and a net loss of CHF 61.6 million reflecting Basilea's investment in the launch of its two hospital anti-infective drugs, Zevtera® and CRESEMBA®.]]>https://www.globenewswire.com/news-release/2015/10/16/776891/10152734/en/Basilea-announces-that-European-Commission-approves-isavuconazole-CRESEMBA-r-as-a-treatment-for-invasive-aspergillosis-and-mucormycosis-in-the-European-Union.html?f=22&fvtc=4&fvtv=20088Basilea announces that European Commission approves isavuconazole (CRESEMBA(r)) as a treatment for invasive aspergillosis and mucormycosis in the European Union2015-10-16T14:55:16Z<![CDATA[BASEL, Switzerland, Oct. 16, 2015 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the European Commission has approved the antifungal isavuconazole for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate. Invasive aspergillosis and mucormycosis are life-threatening fungal infections often occurring in patients with cancer and other immunocompromised patients. Isavuconazole will be marketed in Europe under the trade name CRESEMBA]]>